Konstantinos Kaloulis

Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The company is based in Basel, Switzerland.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

CSEM Centre Suisse d'Electronique et Microtechnique SA provides applied research, technology and consulting services. The firm’s services include contract research and development, small series production, technology transfer, start-ups and ventures, alliance and partnerships, photovoltaics, microsystems, surface engineering and systems. The company was founded in 1984 and is headquartered in Neuchatel, Switzerland.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

NanoDimension Management Ltd is a venture capital firm founded in 2002 by Aymeric Sallin. The firm is headquartered in George Town.

MerLion Pharmaceuticals Pte Ltd. provides drug discovery and development services. It focuses on developing its lead antibacterial candidate, finafloxacin, through early and mid-stage clinical trials. The company was founded in 2002 and is headquartered in Singapore.

Forum Mondial de L'Economie engages in the foremost political, business and cultural organizations to shape global, regional and industry agendas. The company was founded by Klaus Schwab in 1971 and is headquartered in Cologny, Switzerland.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Logitech, Inc. designs, manufactures, and markets cordless products for personal computers, gaming consoles, portable music players, and mobile phones. Its products include audio and video products, webcams, mice, trackballs, keyboards, speakers, headsets, interactive gaming devices, digital pens, and universal remote controls. The company was founded in 1981 and is headquartered in Newark, CA.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

PolyPeptide Laboratories Holding (PPL) AB manufactures commercial therapeutic peptides. The firm offers polypeptide, custom peptide synthesis, peptide synthesis, and generic peptide. The company was founded in 1996 and is headquartered in Malmo, Sweden.

Amazentis SA is a Swiss innovative life science company that focuses on developing products targeting mitochondrial health for advanced nutrition. The company was founded in 2007 by Pierre Landolt, Patrick Aebischer, and Chris Rinsch, and it is currently based in Lausanne, Switzerland. The company has published its research on Mitopure™ Urolithin A in top peer-reviewed scientific journals, including Nature Medicine, Nature Metabolism, JAMA Network Open, and European Journal of Clinical Nutrition. Amazentis has a strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™. Brian Ray has been the CEO of the company since 2023.

Part of Logitech International SA, Logitech SA is a Swiss company that offers a range of award-winning products, including video conferencing solutions for small to large meeting rooms. The company is based in Romanel-sur-Morges, Switzerland. The company's products have been recognized for their design excellence, originality, and innovation by organizations such as Red Dot, Good Design, IF, and IDA. Customers can use an online tool to configure their meeting rooms with the right video conferencing solution.

Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland.

Centre Hospitalier Universitaire Vaudois is a university hospital located in Lausanne, CH. The SwitzerlandUV is also a renowned center of medical education and research, collaborating with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). It has 16 clinical and medico-technical departments and is known for its academic achievements in healthcare, research, and teaching. The vast campus in the lake region is home to these institutions. The CEO of the Swiss company is Nicolas Demartines.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Ribon Therapeutics, Inc. operates as a biotechnology company which focuses on developing therapeutics targeting monoADP-ribosylating PARPs for cancer. Its medicines are used for blocking cancer cells? fundamental survival mechanisms. The company was founded by W. Lee Kraus, Tim Mitchison and Paul Chang in 2015 and is headquartered in Lexington, MA.

CUTISS AG develops bioengineered skin grafts to heal people with skin defects. The company was founded by Ernst Reichmann, Martin Meuli, Daniela Marino, Clemens Schiestl and Fabienne Hartmann-Fritsch and is headquartered in Zurich, Switzerland.

Vandria SA is a Swiss-based company that specializes in mitochondrial therapeutics. The company is based in Lausanne, Switzerland. The company is developing mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. Its lead program, VNA-318, is a brain-penetrant, patent-protected, mitophagy inducer that has shown to improve memory and learning and to have strong disease-modifying effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program that targets ferroptosis. The company was founded by Patrick Aebischer, Chris Rinsch, and Johan Auwerx in 2021 and has raised $20.60m in venture finance. Klaus Dugi has been the CEO of the company since 2021.